Relationship of HbA1c with body weight change over 4 years from starting insulin therapy in people with type 2 diabetes: the CREDIT study

被引：0
|
作者：
Balkau, B. [1 ]
Freemantle, N. [2 ]
Calvi-Gries, F. [3 ]
Pilorget, V. [4 ]
Vincent, M. [4 ]
Home, P. [5 ]
机构：
[1] Univ Paris 11, INSERM, U1018, UMRS 1018, Villejuif, France
[2] UCL, London WC1E 6BT, England
[3] AtlanStat, Reze, France
[4] Sanofi, Paris, France
[5] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
110
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [41] THE IMPACT OF BASELINE HBA1C AND HBA1C TRAJECTORIES ON TIME TO THERAPY ESCALATION IN TYPE 2 DIABETES MELLITUS
    McEwan, P.
    Foos, V
    Larnotte, M.
    VALUE IN HEALTH, 2015, 18 (07) : A698 - A698
  • [42] Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia
    Rosenstock, Julio
    Rendell, Marc
    Gross, Jorge
    Fleck, Penny
    Wilson, Craig
    Mekki, Qais
    DIABETES, 2008, 57 : A132 - A133
  • [43] The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes
    Gelhorn, Heather L.
    Osumili, Beatrice
    Brown, Katelyn
    Ross, Melissa M.
    Schulz, Andrea
    Fernandez, Gabriela
    Boye, Kristina S.
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 793 - 805
  • [44] THE IMPACT OF SUBSTANTIAL IMPROVEMENTS IN HBA1C AND WEIGHT LOSS ON THE MEDICATION PREFERENCES OF PEOPLE WITH TYPE 2 DIABETES
    Gelhorn, H.
    Osumili, B.
    Brown, K.
    Ross, M.
    Schulz, A.
    Fernandez, G.
    Boye, K.
    VALUE IN HEALTH, 2023, 26 (06) : S312 - S313
  • [45] Addition of alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycaemia in patients with type 2 diabetes
    Rendell, M.
    Rosenstock, J.
    Gross, J.
    Fleck, P.
    Wilson, C.
    Mekki, Q.
    DIABETOLOGIA, 2008, 51 : S37 - S38
  • [46] Dapagliflozin therapy for Type 2 diabetes in primary care: effects on HbA1c, weight and blood pressure over two years follow-up
    Wilding, J.
    Bailey, C.
    Rigney, U.
    Blak, B.
    Kok, M.
    Emmas, C.
    DIABETIC MEDICINE, 2017, 34 : 189 - 189
  • [47] Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study
    Forbes, Angus
    Murrells, Trevor
    Mulnier, Henrietta
    Sinclair, Alan J.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06): : 476 - 486
  • [48] In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
    Lipscombe, Lorraine L.
    ANNALS OF INTERNAL MEDICINE, 2019, 171 (04) : JC16 - JC16
  • [49] Diabetes education lowers HbA1c and weight in a veteran population with Type 2 Diabetes
    Tacker, Deanna
    Harris, Margaret M.
    Carroll, Polly
    Hays, Nicholas
    Johnson, Pippa
    Hakkak, Reza
    FASEB JOURNAL, 2007, 21 (05): : A304 - A304
  • [50] Naltrexone SR/Bupropion SR Therapy Reduced Body Weight and HbA1c in Overweight/Obese Women with Type 2 Diabetes
    Hollander, Priscilla
    Loper, Judy
    Mignon, Laurence
    Burns, Colleen
    Harris-Collazo, Raul
    Kim, Dennis
    DIABETES, 2011, 60 : A502 - A503
12345